Myriad Genetics Files Form S-3 Shelf Registration for Outstanding Shares of Common Stock
SALT LAKE CITY, April 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- Myriad Genetics, Inc.
(Nasdaq: MYGN), announced today that it has filed an S-3 Registration
Statement with the Securities and Exchange Commission. The shelf registration
allows the Company to sell up to $300 million of various types of securities.
The Company has no immediate plans to offer or sell any of its securities.
The terms of any sale would be announced in a filing with the SEC at the time
of any such sale.
The shelf registration statement was filed today with the Securities and
Exchange Commission but has not yet become effective. The common stock may
not be sold nor may offers to buy be accepted prior to the time the
registration statement becomes effective. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy, nor shall
there be any sale of these securities in any state in which such an offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
Myriad Genetics, Inc. is a biopharmaceutical company focused on the
development of novel healthcare products. The Company develops and markets
predictive medicine products, and is developing and intends to market
therapeutic products. Myriad's news and other information are available on the
Company's Web site at www.myriad.com.
This press release may contain "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward looking statements are based on management's current expectation and
are subject to certain risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by forward-looking
statements. These include, but are not limited to, uncertainties as to the
extent of future government regulation of Myriad Genetics' business;
uncertainties as to whether Myriad Genetics and its collaborators will be
successful in developing, and obtaining regulatory approval for, and
commercial acceptance of, therapeutic compounds; the risk that markets will
not exist for therapeutic compounds that Myriad Genetics develops or if such
markets exist, that Myriad Genetics will not be able to sell compounds, which
it develops, at acceptable prices; and the risk that the Company will not be
able to sustain revenue growth for its predictive medicine business and
products. These and other risks are identified in the Company's filings with
the Securities and Exchange Commission, including the Company's Annual Report
on Form 10-K for the fiscal year ended June 30, 2004. All information in this
press release is as of April 7, 2005, and Myriad undertakes no duty to update
this information unless required by law.
SOURCE Myriad Genetics, Inc.
William A. Hockett, Vice President of Corporate Communications of Myriad Genetics,
Inc., +1-801-584-3600, bhockett@myriad.com
|
